linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth

Pharma

1
Pharma

Japan’s AnGes preps capacity for 1 million doses as vaccine development continues

The country hopes to counter any second wave of infections by building production capacity while vaccines are still in the works. AnGes is developing a DNA vaccine that will use genetic material from the coronavirus to stimulate the production of human antibodies against the disease. The vaccine is expected to begin clinical trials soon.

22 Jun 20200 comment
Pharma

Vaccine development takes years. But one for the pandemic by early 2021? Here’s a reality check.

Around 120 Covid-19 vaccines are under research across the world. Besides being a long-drawn process, the lack of convincing data and the fickle nature of the novel coronavirus would call for a tempered expectation of a vaccine. But some scientists have promised that millions of doses will be available by early 2021. So, what’s fuelling such optimism?

headset AUDIO SUMMARY . 01:16
Pharma

A tale of clinical and other trials: Gilead’s anti-virus drug has a long battle to fight — beyond the lab

Remdesivir has emerged as a potential drug to fight Covid-19. Gilead, its maker, recently secured regulatory approvals in the US and Japan. It has also signed deals with Indian drug makers like Cipla and Jubilant. But to be considered a game changer, it will have to overcome a host of challenges even after it gets a final stamp of approval.

headset AUDIO SUMMARY . 01:22
[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]